Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.57 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.55 |
| ▸ | UBE2M | P61081 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574819 | 0.91 | GRIN2B (0.59) | GRIN2BDCUN1D1UBE2MGAALMNA | |
| SCHEMBL1575216 | 0.90 | GRIN2B (0.58) | GRIN2BGAALMNAMAPTEPHX2 | |
| SCHEMBL1574522 | 0.88 | GRIN2B (0.45) | GRIN2BDCUN1D1UBE2MLMNAMAPT | |
| SCHEMBL1575548 | 0.86 | GRIN2B (0.58) | GRIN2BDCUN1D1UBE2MGAALMNA | |
| SCHEMBL1575364 | 0.86 | CYP2D6 (0.50) | LMNAMAPTEPHX2MEN1KMT2A | |
| SCHEMBL1575665 | 0.85 | GRIN2B (0.56) | GRIN2BDCUN1D1UBE2MGAALMNA | |
| SCHEMBL1573940 | 0.85 | ALDH1A1 (0.56) | GRIN2BGAALMNAMAPTEPHX2 | |
| SCHEMBL1574748 | 0.84 | GRIN2B (0.63) | GRIN2BGAALMNAMAPTEPHX2 | |
| SCHEMBL1574779 | 0.84 | NPSR1 (0.55) | GRIN2BMAPTEPHX2MEN1KMT2A | |
| SCHEMBL1574781 | 0.83 | GRIN2B (0.50) | GRIN2BMAPTTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | GRIN2B 3001/4885DCUN1D1 3316/4885UBE2M 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.